Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine | NEJM
NIH begins clinical trial evaluating second COVID-19 booster shots in adults | National Institutes of Health (NIH)
How To Improve Patient Recruitment In Clinical Trials? | Credevo Articles
A Bivalent Omicron-Containing Booster Vaccine against Covid-19 | NEJM
Department of Health and Social Care on Twitter: "Everyone aged 16 and over is eligible for the #COVID19 booster from three months after their second dose. Book an appointment online or find
GCT to Perform Booster Visits in Russia
Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial | Nature Medicine
Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and ...
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial - The Lancet
Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age | NEJM
UK volunteers to receive Moderna Omicron COVID-19 booster vaccine in clinical study | NIHR
Protocol for a multicentre randomised controlled trial examining the effects of temporarily pausing Bruton tyrosine kinase inhibitor therapy to coincide with SARS-CoV-2 vaccination and its impact on immune responses in patients with
COVID vaccinations: questions and answers about the rollout in North Yorkshire - NHS North Yorkshire CCG
Vaccines
Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial -
Antibody persistence and immune memory response following primary vaccination and boosting with live attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) in Bangladesh: A phase 4 open-label clinical trial - ScienceDirect
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial - The Lancet Infectious Diseases
Immunobridging trials: Bringing medicines to patients faster
Ongoing booster vaccine trial seeks vaccinated volunteers | Newsroom
Volunteers needed for COVID-19 booster trial | KPWHRI
Virology Research Clinic - University of Washington
Virology Research Clinic - University of Washington
